stockrow
Friday 6 November 2026
Export ILMN’s income statement to Excel — free account
Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.
- Revenue
- +4.15%
- EPS
- +49.0%
- Free cash flow
- +49.8%
- Total debt
- +80.0%
Quarter to September 2026, against a year earlier
209.82
16.72
−7.38%
Follow ILMN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
46.47 | 32.50 | 22.29 | 23.93 |
+8 more quarters Free account |
P/S ratio |
9.11 | 5.91 | 4.29 | 4.68 | |
P/FCF ratio |
39.66 | 28.99 | 19.67 | 22.19 | |
P/Operating CF |
98.63 | 132.09 | 65.26 | 63.33 | |
P/B ratio |
13.14 | 9.36 | 7.05 | 7.47 | |
Price to Tangible BV |
28.11 | 23.21 | 19.60 | 14.52 | |
EV/Sales |
9.31 | 6.09 | 4.48 | 4.76 | |
EV/EBITDA |
34.14 | 23.69 | 17.54 | 19.20 | |
EV/Operating CF |
34.36 | 24.99 | 17.45 | 19.16 | |
EV/FCF |
40.56 | 29.87 | 20.52 | 22.57 | |
Quick Ratio |
1.80 | 1.22 | 1.21 | 1.57 | |
Current Ratio |
2.63 | 1.80 | 1.75 | 2.08 | |
Net Debt/EBITDA |
1.20 | 1.03 | 1.21 | (0.53) | |
Debt/Assets |
26.26% | 22.42% | 22.72% | 22.43% | |
Debt/Equity |
0.57 | 0.53 | 0.56 | 0.55 | |
Asset Turnover |
0.70 | 0.71 | 0.69 | 0.67 | |
Operating CF/Net income |
1.90 | 0.97 | 2.16 | 0.96 | |
Capex/Depreciation |
(0.56) | (0.57) | (0.55) | (0.83) | |
Interest Coverage |
12.71 | 10.21 | 8.71 | 7.77 | |
Research and Development Expense of Revenue |
21.61% | 21.74% | 22.00% | 20.62% | |
Selling, General and Administrative Expense of Revenue |
24.89% | 23.55% | 24.93% | 26.57% | |
Intangible Assets out of Total Assets |
0.25 | 0.25 | 0.26 | 0.20 | |
Share Based Compensation of Revenue |
6.55% | 6.30% | 5.50% | 5.44% | |
Graham Net Nets |
(0.02) | (0.04) | (0.06) | (0.03) | |
Graham Number |
52.54 | 47.83 | 46.65 | 46.54 | |
Earnings Yield |
2.15% | 3.08% | 4.49% | 4.18% | |
Free Cash Flow Yield |
2.52% | 3.45% | 5.09% | 4.51% | |
Revenue per Share |
7.48 | 7.68 | 7.13 | 7.48 | |
Operating CF per Share |
2.77 | 1.33 | 1.89 | 2.07 | |
Capex per Share |
(0.26) | (0.26) | (0.25) | (0.35) | |
Free Cash Flow per Share |
2.51 | 1.07 | 1.64 | 1.72 | |
Cash per Share |
8.85 | 7.74 | 7.55 | 10.54 | |
Shareholders Equity per Share |
20.83 | 18.79 | 17.49 | 17.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
20.83 | 18.79 | 17.49 | 17.57 | |
Free Cash Flow |
379.00 | 161.00 | 251.00 | 266.00 | |
Working Capital |
1,879.00 | 1,256.00 | 1,172.00 | 1,704.00 | |
Capital Expenditures |
(40.00) | (40.00) | (38.00) | (55.00) | |
Net Current Asset Value |
(632.00) | (978.00) | (1,145.00) | (632.00) | |
EV/EBIT |
43.98 | 30.99 | 23.10 | 25.62 | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.05 | |
Price to Operating Income |
43.00 | 30.07 | 22.13 | 25.19 | |
| Other line items | |||||
Average Receivables |
733.50 | 732.50 | 718.50 | 794.50 | |
Average Payables |
229.50 | 215.00 | 212.50 | 230.50 | |
Average Inventory |
628.50 | 602.00 | 574.00 | 555.50 | |
Average Assets |
6,494.50 | 6,368.50 | 6,370.50 | 6,473.50 | |
Average Common Equity |
2,763.00 | 2,548.00 | 2,522.00 | 2,548.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026